메뉴 건너뛰기
Gastric Cancer
Volumn 14, Issue 1, 2011, Pages 1-3
Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment
Author keywords

[No Author keywords available]
Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; TAXANE DERIVATIVE;
EID: 79951957494     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-011-0018-4     Document Type: Editorial
Times cited : (1)
References (7)
  • 1
    • 79953025190 scopus 로고    scopus 로고
    • Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
    • doi: 10.1007/s10120-011-0009-5
    • Narahara H, Iishi H, Imamura H, Tuburaya A, Chin K, Imamoto H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer, doi: 10.1007/s10120-011-0009-5.
    • Gastric Cancer
    • Narahara, H.1    Iishi, H.2    Imamura, H.3    Tuburaya, A.4    Chin, K.5    Imamoto, H.6
  • 2
    • 48849094297 scopus 로고    scopus 로고
    • Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
    • 18558665 10.1093/annonc/mdn166 1:STN:280:DC%2BD1cvotFCmtA%3D%3D
    • M Dank J Zaluski C Barone V Valvere S Yalcin C Peschel, et al. 2008 Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Ann Oncol 19 1450 1457 18558665 10.1093/annonc/mdn166 1:STN:280: DC%2BD1cvotFCmtA%3D%3D
    • (2008) Ann Oncol , vol.19 , pp. 1450-1457
    • Dank, M.1    Zaluski, J.2    Barone, C.3    Valvere, V.4    Yalcin, S.5    Peschel, C.6
  • 3
    • 71249128928 scopus 로고    scopus 로고
    • Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomized phase 3 study
    • 19818685 10.1016/S1470-2045(09)70259-1 1:CAS:528:DC%2BD1MXhtlGit7bI
    • N Boku S Yamamoto H Fukuda K Shirao T Doi A Sawaki, et al. 2009 Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study Lancet Oncol 10 1063 1069 19818685 10.1016/S1470-2045(09)70259-1 1:CAS:528:DC%2BD1MXhtlGit7bI
    • (2009) Lancet Oncol , vol.10 , pp. 1063-1069
    • Boku, N.1    Yamamoto, S.2    Fukuda, H.3    Shirao, K.4    Doi, T.5    Sawaki, A.6
  • 4
    • 40749153540 scopus 로고    scopus 로고
    • Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer
    • 18282805 10.1016/S1470-2045(08)70035-4 1:CAS:528:DC%2BD1cXivVaqtb4%3D
    • W Koizumi H Narahara T Hara A Takagane T Akiya M Takagi, et al. 2008 Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer Lancet Oncol 9 215 221 18282805 10.1016/S1470-2045(08)70035-4 1:CAS:528:DC%2BD1cXivVaqtb4%3D
    • (2008) Lancet Oncol , vol.9 , pp. 215-221
    • Koizumi, W.1    Narahara, H.2    Hara, T.3    Takagane, A.4    Akiya, T.5    Takagi, M.6
  • 5
    • 18744373000 scopus 로고    scopus 로고
    • Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with advanced gastric cancer: JCOG study 9205
    • 12506170 10.1200/JCO.2003.04.130 1:CAS:528:DC%2BD2cXpsVWru7k%3D
    • A Ohtsu Y Shimada K Shirao N Boku I Hyodo H Saito, et al. 2003 Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with advanced gastric cancer: JCOG study 9205 J Clin Oncol 21 54 59 12506170 10.1200/JCO.2003.04.130 1:CAS:528:DC%2BD2cXpsVWru7k%3D
    • (2003) J Clin Oncol , vol.21 , pp. 54-59
    • Ohtsu, A.1    Shimada, Y.2    Shirao, K.3    Boku, N.4    Hyodo, I.5    Saito, H.6
  • 6
    • 79953028051 scopus 로고    scopus 로고
    • Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC): Results from combined analysis of JCOG9205 and JCOG9912 [abstract no.4061]
    • A Takashima N Boku K Kato J Mizusawa K Nakamura H Fukuda, et al. 2010 Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC): results from combined analysis of JCOG9205 and JCOG9912 [abstract no.4061] J Clin Oncol 28 Suppl 15S 4061
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15S , pp. 4061
    • Takashima, A.1    Boku, N.2    Kato, K.3    Mizusawa, J.4    Nakamura, K.5    Fukuda, H.6
  • 7
    • 77951983624 scopus 로고    scopus 로고
    • Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) [abstract no. 4540]
    • PC Thuss-Patience A Kretzschmar T Deist A Hinke D Bichev B Lebedinzew, et al. 2009 Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) [abstract no. 4540] J Clin Oncol 27 Suppl 15S 4540
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. 15S , pp. 4540
    • Thuss-Patience, P.C.1    Kretzschmar, A.2    Deist, T.3    Hinke, A.4    Bichev, D.5    Lebedinzew, B.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.